Full-Time
Assistant Chef de Projet
Updated on 9/9/2026
Advanced Biological Laboratories
Medical technology and diagnostics software provider
No salary listed
Marseille, France
In Person
 Biology & Biotech (1) |
|---|
- A scientific education at Bac+3 level or equivalent.
- Interpersonal skills, initiative, and ability to work as part of a team.
- Proficiency in Microsoft Office and English.
- Ability to adapt, multitask, and work in a dynamic environment.
- Monitor clinical-trial activities on a daily basis in accordance with client specifications and deadlines.
- Monitor sample-kit inventory and manage orders from investigator sites in coordination with the production department.
- Manage transport of biological samples from investigator sites or CDL Pharma to destination laboratories in accordance with applicable regulations.
- Verify data, prepare and send queries to investigator sites, and follow them through resolution.
- Track activities, validate supplier invoices, and prepare client invoices.
- Maintain traceability of completed tasks according to internal procedures and good clinical practices.
- Coordinate with project stakeholders, including sponsors, investigator sites, laboratories, suppliers, and subcontractors.
- Support clinical-trial setup by preparing client specifications, internal documents, and laboratory manuals for investigator sites.
- Participate in development and monitoring of the quality system in an ISO 9001 environment, including nonconformity management, procedure writing, and audits.
Advanced Biological Laboratories provides software, assays, and IT solutions for infectious disease diagnostics and clinical genotyping. It supports molecular detection, sequencing-based genotyping, and data analysis for pathogens such as HIV, SARS-CoV-2, HBV, HCV, and tuberculosis, compatible with Sanger and Next Generation Sequencing. The company earns recurring revenue by offering end-to-end solutions for labs and researchers, including CRO services and assay manufacturing through acquisitions. Its aim is to deliver integrated tools that streamline detection, drug-resistance analysis, and data-driven patient management in infectious diseases.
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
Luxembourg, Luxembourg
Founded
2000
Simplify's Take
What believers are saying
- July 2026 UltraGene Viral Meningitis and Respiratory Pathogens 21 launched commercially.
- April 2026 new private investor strengthened ABL Luxembourg without changing control.
- BSI partnership targets DeepChek class C compliance by 2028 and UltraGene class B by 2029.
What critics are saying
- February and July 2026 ABL sold ABL Diagnostics blocks, signaling financing pressure.
- February 2026 ProPhase reverse-merger collapsed, delaying a U.S. listing path.
- IVDR deadlines and legacy-device rules can strand Fast Track assays before 2029.
What makes Advanced Biological Laboratories unique
- 2000 Luxembourg spin-off, combining infectious-disease assays, sequencing software, and data analytics.
- DeepChek, UltraGene, and OpenChek span HIV, hepatitis, tuberculosis, and CNS diagnostics.
- Fast Track Diagnostics assets plus BSI-backed IVDR transition widen assay breadth and compliance.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Professional Development Budget
Company News
Introduction of a minimum floor price of €4.50 per share for any future drawdown Reduction of the maximum drawdown size from 50,000 to 2,500 shares Immediate return of 98,026 loaned
ABL Diagnostics has announced the commercial availability of UltraGene Viral Meningitis, a multiplex real-time PCR assay for detecting viral pathogens associated with meningitis and central nervous system infections. The test can identify six viruses from cerebrospinal fluid specimens, including HSV-1, HSV-2, and Enterovirus. The product originates from the former Fast Track Diagnostics portfolio, which ABL acquired from Siemens Healthineers in 2025. It has obtained CE-IVD registration under Council Directive 98/79/EC through ABL SA Luxembourg. The assay can be automated on ABL Diagnostics' OpenChek platform, enabling laboratories to streamline sample processing. ABL Diagnostics will handle worldwide commercialisation and distribution, with availability across Europe, the Middle East, Africa, Asia, and Latin America. The company is working towards compliance with the European IVDR regulatory framework as part of its long-term strategy.
Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based medtech and biotechnology company, has announced the entry of a new private investor through a minority shareholding acquisition. Existing shareholders retain control, with governance arrangements unchanged. ABL Luxembourg serves as parent company to Euronext-listed ABL Diagnostics and operates as an active technological platform with expertise in healthcare information systems and sequencing data analysis. The company has distributed dividends regularly since 2021. The group's subsidiaries include CDL Pharma, which recently consolidated pharmaceutical activities, and Humedics, focused on biomedical research. ABL announced in 2025 the acquisition of Fast Track Diagnostics' intangible assets. The company has also entered preliminary discussions regarding potential US market entry, though no definitive agreement has been reached.
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company.
Advanced Biological Laboratories S.A. (“ABL Luxembourg”) is pleased to announce the signing of a new share purchase agreement with Alumni Capital, a U.S.-based